Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.
The conversation humorously discusses the complexity of understanding and treating male pattern hair loss, mentioning treatments like Minoxidil, finasteride, RU58841, Dr. Brotzu's lotion, and Dr. Tsuji's hair cloning. The original post satirically claims that only those with high intelligence can appreciate these treatments.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.
A user shared their positive experience with a hair transplant in Turkey, where they received 3500 grafts. They started using finasteride, minoxidil, biotin, and ajuga reptans supplements after one month, and posted progress pictures at 1, 2, and 6 months post-transplant.
Kintor Pharma completed patient enrollment for a Phase II trial in China for GT20029, a potential new treatment for hair loss. Some believe GT20029 could replace finasteride if effective, while others discuss finasteride's limited efficacy and potential underreported side effects.
RU58841 has significantly improved the user's hair loss experience, alongside oral finasteride, dutasteride, 5 mg minoxidil, topical finasteride, dermastamping, and low-level laser therapy. The user is considering increasing their RU58841 dose from 75 mg to 100-150 mg daily.
A user shared their positive experience and results 10 months after a hair transplant at Mercure Istanbul Clinics, using 3000 grafts. They expressed satisfaction with both the outcome and the clinic's service.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.
The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.
The user feels insecure about hair loss and is seeking affordable solutions, as hair transplants are too expensive. They are looking for advice on treatments like Minoxidil, finasteride, or RU58841.
A 27-year-old woman with androgenic alopecia is losing hair despite using oral minoxidil and spironolactone, and is considering dutasteride. She is exploring causes like stress and medication side effects, planning tests, and considering treatment changes.
The conversation discusses seeking a stronger treatment than Dutasteride (DUT) for hair loss. Suggestions include combining DUT with RU58841, increasing DUT dosage, and using transgender hormone replacement therapy or testosterone blockers, though some options may have feminizing side effects.
RU and Pyri block androgen receptors to prevent hair loss but may also hinder hair regrowth since they prevent testosterone, which can stimulate hair growth, from binding to these receptors. The user is questioning if this understanding is correct.
Topical Dutasteride is more effective than topical Finasteride for treating AGA in men, with fewer side effects. Mesotherapy with Dutasteride, administered every 3 months, shows promising results for hair regrowth and maintenance without daily routines or significant side effects.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
A 23-year-old male with aggressive hair loss has tried various treatments, including minoxidil (both topical and oral), dutasteride, multivitamins, and PRP sessions, but has seen limited success. He is considering a hair transplant and seeks advice on whether this is a reasonable approach.
The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.
A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.
The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.
Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.
Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.
Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.
The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.